Cable Hill Partners’s Haemonetics HAE Stock Holding History

Cable Hill Partners’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-36	Closed	-$3K	–	363
2019 Q1	$3K	Hold	36	–	–	﹤0.01%	697
2018 Q4	$4K	Buy	+36	New	+$3.78K	﹤0.01%	597

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Cable Hill Partners's HAE Position: Q2 2019 in Review

Cable Hill Partners sold out of Haemonetics (HAE) in Q2 2019, closing a stake of 36 shares — an estimated $3K sold.

Cable Hill Partners first reported a position in HAE in Q4 2018 and held it in 2 quarters. The position peaked at $4K in Q4 2018. 256 funds tracked by Wall St. Rank hold HAE as of Q2 2019.

Cable Hill Partners reported no remaining Haemonetics position as of Q2 2019 after selling out during the quarter.
Cable Hill Partners sold 36 Haemonetics shares in Q2 2019, an estimated $3K.
Cable Hill Partners first reported a position in Haemonetics in Q4 2018 and held it in 2 quarters.
Cable Hill Partners's Haemonetics position peaked at $4K in Q4 2018.
256 funds tracked by Wall St. Rank held Haemonetics as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.